Stock Price, News, Quote and Profile of CALIDI BIOTHERAPEUTICS INC(NYSEARCA:CLDI) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

CALIDI BIOTHERAPEUTICS INC

NYSEARCA:CLDI (5/8/2024, 7:04:02 PM)

After market: 0.2287 -0.01 (-4.31%)

0.239

+0.01 (+5.43%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap8.54M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

American Stock Exchange Stock Screener

Find more stocks on American Stock Exchange

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

First Light Acquisition Group, Inc. is a blank check company, which formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more entities. The company is headquartered in San Diego, California. The company went IPO on 2021-09-10. The firm is engaged in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to patient safety. This dual approach can potentially treat, or even prevent, metastatic disease. The company is engaged in developing allogenic stem cell-based delivery platforms designed to deliver a new generation of targeted immunotherapies for the treatment of cancer. These platforms include CLD-101 (NeuroNova) and CLD-201 (SuperNova).